Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when SS-31 crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence173 certificate records mentioning this compound or product name81 provider-linked · 127 exact product matches

Status

Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area

Longevity research

Primary research area: Longevity. Also surfaces under Tissue repair for browsing and discovery.

Aliases

Elamipretide

Signal depth

Medium

FDA label signal · 32 trials · 464 PubMed results

Promising

Research evidence

SS-31 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

SS-31 has 32 name-matched clinical trials (3 international) (highest phase: Phase 4) and 464 PubMed-indexed publications and is not FDA-approved. 14 trials have posted results. Note: 1 retracted publication in the literature.

🌍 3 international trials⚠ 1 retracted publication

Human data

Phase 3

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

High-impact

PHASE3 · RandomizedReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)PHASE3 · RandomizedA Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension PHASE3 · RandomizedStudy to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)ISRCTN · Phase 4A Phase IIIb/IV, randomized, double-blind, parallel-group, placebo-controlled, trial to evaluate the efficacy and safety of daily subcutaneous injections of elamipretide in patients with genetically confirmed Barth syndrome ISRCTN · Phase 3ReNEW: a clinical trial investigating the efficacy and safety of elamipretide in subjects who have dry age-related macular degeneration (Dry AMD)Journal of the American Society of Nephrology · 490 citationsThe Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What SS-31 is

SS-31 is a mitochondria-targeted peptide commonly referenced in energy, recovery, and aging-related research discussions. In development contexts it is often referred to as elamipretide.

Why it matters

It sits in the same broad mitochondrial-interest lane as MOTS-c and humanin, but with a more explicit investigational-development framing.

Regulatory context

SS-31 is not FDA approved in the United States. It is better classified here as investigational rather than as an approved therapy.

Practical reading note

Mitochondrial peptides often sound especially advanced in marketing copy, so it helps to distinguish mechanistic intrigue from actual clinical availability.